Tag Archives: AMGN

Best Biotech Stocks To Watch For 2018

Ionis Pharmaceuticals (NASDAQ:IONS) is a biotech company which develops RNA-targeted therapeutics and has been operating for over 26 years. The company has recently filed to spin-off its Akcea Therapeutic segment, focused on Volanesorsen and other drugs related to cardiometabolic diseases originated by lipid disorders.

Ionis Core, the company core segment, has developed a broad pipeline of....More>>>

Top Energy Stocks To Own For 2019

Anyone who was smart enough to buy Netflix (NASDAQ:NFLX) at its IPO in 2002 and hold until today is sitting on a gain of 27,430%. That’s a high enough return to turn a small amount of money into life-changing wealth.

So, which stocks do we think are capable of delivering gains like that for shareholders who buy today? We asked a team of investors to weigh in, and they pickedSolarEdge....More>>>

Hot Biotech Stocks To Own For 2018


The biotech sector saw a modest uptick this week amid a slew of biotech earnings news flow and a deal announced in the space: Link

Retailers have shown greater capital discipline in the hopes of re-invigorating their businesses, but investors must take a cautious stance on the sector, according to Morgan Stanley: Link

President Donald Trump said he was working....More>>>

Top 10 Biotech Stocks To Watch For 2018

Most of the time, quarterly financial results are important for companies. Investors eagerly await the update on revenue and earnings. But for Celldex Therapeutics (NASDAQ:CLDX), it’s a different story.

The big news everyone anxiously looked forward to for the clinical-stage biotech was the results from a pivotal clinical study glembatumumab vedotin (glemba) in treatingtriple negative....More>>>

Top 5 Biotech Stocks To Watch For 2019

Aclaris Therapeutics (NASDAQ:ACRS) received a $50.00 price target from equities research analysts at Cantor Fitzgerald in a report issued on Tuesday. The brokerage presently has a “buy” rating on the biotechnology company’s stock. Cantor Fitzgerald’s price target indicates a potential upside of 177.62% from the company’s current price.

ACRS has been the subject....More>>>

Hot Biotech Stocks To Buy For 2018

On November 25th, 2017, I first wrote about a small biotech called KemPharm (KMPH) and emphasized the importance of the ADHD portion of KemPharm’s pipeline. I wrote about Apadaz and the pain portion of KemPharm’s pipeline as somewhat of a liability, but believed that the substantial potential of the ADHD pipeline made the potential benefit outweigh the risks. On the next trading day....More>>>

Top 5 Biotech Stocks To Buy For 2018

Here’s what Jim Cramer had to say about some of the stocks during the Mad Money Lightning Round:

Waste Management (WM) : “This is a high quality stock so I’m not going to bet against it.”

The Blackstone Group (BX) : “I think this is a terrific buy.”

Xilinx (XLNX) : “I think it’s time to start getting back into NVIDIA (NVDA) .”


Top 10 Biotech Stocks To Watch For 2018

Puma Biotechnology Inc (NASDAQ:PBYI) files its latest 10-K with SEC for the fiscal year ended on December 31, 2017. Puma Biotechnology Inc is a biopharmaceutical company. It is engaged in the acquisition, development and commercialization of products to enhance cancer care. Puma Biotechnology Inc has a market cap of $3.03 billion; its shares were traded at around $80.75 with and P/S ratio of 495.40.....More>>>

Hot Biotech Stocks To Watch For 2019

Revance Therapeutics, Inc. (NASDAQ: RVNC) shares jumped 33.7 percent to $34.75 after the company disclosed that its RT002 met primary and all secondary endpoints.
Barnes & Noble Education, Inc. (NYSE: BNED) shares climbed 21.5 percent to $7.6200 after the company reported Q2 results.
Moleculin Biotech, Inc. (NASDAQ: MBRX) shares gained 18.9 percent to $2.1631 after....More>>>

Top 10 Biotech Stocks To Buy For 2018

Welcome to another edition of “3 Things In Biotech You Should Learn Today,” a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research.

Merck has bad news in stomach cancer therapy

Company: Merck (MRK)

Therapy: Pembrolizumab

Disease: Gastric or gastroesophageal junction (GEJ) cancer